# Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

> **NCT06393985** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 30 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Decitabine, venetoclax and blinatumomab

## Key facts

- **NCT ID:** NCT06393985
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-25
- **Primary completion:** 2026-04-25
- **Final completion:** 2027-04-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393985, "Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06393985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*